2023
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
Xiong Y, Campbell B, Fisher M, Schwamm L, Parsons M, Li H, Pan Y, Meng X, Zhao X, Wang Y. Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial. Stroke And Vascular Neurology 2023, 9: 82-89. PMID: 37247876, PMCID: PMC10956103, DOI: 10.1136/svn-2023-002310.Peer-Reviewed Original ResearchLarge vessel occlusionAnterior circulation large vessel occlusionIschemic strokePerfusion-weighted imagingEfficacy outcomesReperfusion therapyMajor neurological improvementSecondary efficacy outcomesStandard medical therapyHealth Stroke ScalePrimary efficacy outcomeSymptomatic intracerebral hemorrhageRankin Scale scoreTissue-type plasminogen activatorDirect thrombectomyNeurological improvementStroke ScaleAnterior circulationMedical therapyMRS scoreIntracerebral hemorrhageSalvageable tissueVessel occlusionCT perfusionClinical trials
2022
A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design
Albers G, Campbell B, Lansberg M, Broderick J, Butcher K, Froehler M, Schwamm L, Nouh A, Liebeskind D, Toy F, Yang M, Massaro L, Schoeffler M, Purdon B. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design. International Journal Of Stroke 2022, 18: 237-241. PMID: 35262424, DOI: 10.1177/17474930221088400.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeInternal carotid arteryPlacebo-controlled trialRankin Scale scoreSymptom onsetDay 90Scale scoreMiddle cerebral artery occlusionEfficacy of tenecteplaseLate-window patientsSafety of tenecteplaseSymptomatic intracranial hemorrhageCerebral artery occlusionLarge vessel occlusionPhase IIIPrimary efficacy objectiveBetter clinical outcomesAdverse eventsArtery occlusionEndovascular thrombectomyIschemic strokeMCA occlusionClinical outcomesIntracranial hemorrhageSalvageable tissue
2020
Thrombolysis beyond 4.5 h in Acute Ischemic Stroke
Etherton M, Gadhia R, Schwamm L. Thrombolysis beyond 4.5 h in Acute Ischemic Stroke. Current Neurology And Neuroscience Reports 2020, 20: 35. PMID: 32607627, DOI: 10.1007/s11910-020-01055-1.Peer-Reviewed Original ResearchConceptsUnknown symptom onsetSymptom onsetAcute ischemic stroke patientsImproved long-term outcomesSalvageable brain tissueIntravenous thrombolytic therapyPlacebo-controlled trialAcute ischemic strokeIschemic stroke patientsLong-term outcomesDWI-FLAIR mismatchAlteplase treatmentSummaryIn patientsIschemic strokeStroke onsetAcute settingRecent FindingsIn recent yearsStroke patientsThrombolytic therapySalvageable tissueReviewThe purposeIndividualized approachStroke lesionsPatientsBrain tissue
2018
Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset
Etherton M, Barreto A, Schwamm L, Wu O. Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset. Frontiers In Neurology 2018, 9: 327. PMID: 29867736, PMCID: PMC5962731, DOI: 10.3389/fneur.2018.00327.Peer-Reviewed Original ResearchReperfusion therapyIschemic strokeSalvageable ischemic tissueAcute ischemic strokePivotal clinical trialsTreatment of patientsNumber of patientsRisk of infarctionLow treatment ratesUnwitnessed strokeIntravenous alteplaseEndovascular thrombectomyHospital arrivalStroke onsetRevascularization therapySalvageable tissueUnknown onsetClinical trialsClinical dilemmaIschemic tissueStroke researchPatientsTreatment ratesStrokeTherapy
2001
Heterogeneous spatial-temporal evolution of DWI/PWI in human cerebral ischemia
Wu O, Schwamm L, Koroshetz W, Gonzalez R, Pan V, Benner T, Copen W, Ostergaard L, Sorensen A. Heterogeneous spatial-temporal evolution of DWI/PWI in human cerebral ischemia. Stroke 2001, 32: 348-348. DOI: 10.1161/str.32.suppl_1.348-d.Peer-Reviewed Original ResearchCerebral blood flowHuman cerebral ischemiaDWI/PWICerebral blood volumeMean transit timeApparent diffusion coefficientFractional anisotropyCerebral ischemiaRim tissueHuman ischemic strokeElevated fractional anisotropyTwo-sample t-testDWI abnormalitiesInitial DWIIschemic strokeMCA territoryAcute stageIschemic coreSalvageable tissueIntralesional heterogeneityIschemic tissueBlood flowBlood volumeRisk tissuePatients